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Objective/background: Molecular-based, rapid drug-susceptibility tests are needed to guide
the appropriate use of new drugs and new therapeutic regimens at the programmatic level,
and to prevent a further increase in the incidence of drug-resistant tuberculosis (TB).
Experts have recognized the need for a global, curated, and standardized analysis and
data-sharing platform that provides a one-stop data source for clinically relevant genotypic
and phenotypic information on Mycobacterium tuberculosis.
Methods: To this purpose, the Relational Sequencing TBData Platform (ReSeqTB) consortium
has critically reviewed themost inclusive set of published data onmutations associatedwith
drug resistance in M. tuberculosis to date, and has graded a comprehensive list of globally
prevalent mutations based on the strength of their association with drug resistance.
Results and Conclusions: ReSeqTB serves as a single repository for the compilation, curation,
and validation of existing and newly created sequences and metadata on M. tuberculosis
strains and will use the currently reviewed data set, validated by international experts, as
a starting point until sufficient new sequence data are accumulated. This initiative is sup-
ported by a global partnership of academic institutions, public health agencies, and non-
governmental organizations including the Critical Path Institute, FIND, the World Health
Organization, the New Diagnostics Working Group, the U.S. Centers for Disease Control
and Prevention, and the National Institute of Allergy and Infectious Diseases and it is finan-
cially supported by the Bill & Melinda Gates Foundation.
Key strengths of the ReSeqTB Database include the following:
 A user-friendly interface designed for nonexpert or expert operability.
 A standardized and validated analysis pipeline for variant analyses of M. tuberculosis
next-generation sequencing (NGS) data.
 Access to data beyond the published literature with dynamic and iterative updates of
new data generated by global surveillance and clinical trials.
 Awell-developed legal structure to ensure intellectual property rights and data owner-
ship remain with contributors.
 A structured data-sharing architecture to restrict access to sensitive or unpublished
data sets.
 Metadata standardization using CDISC: supports global, platform-independent data
standards that enable information system interoperability.
 An emphasis on data quality and rigorous, expert curation with multiple quality con-
trol checks for whole-genome sequencing and other metadata.iol. (2016),
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conferring mutations based on rigorous statistical standards.
 Regulatory-compliant analysis pipeline and database architecture.
Successful execution of such an extensive database platform requires substantial collabo-
ration from scientists investigating the genetic basis for drug resistance worldwide, and
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